Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

被引：0
|
作者：
Sue Ping Thang
Mei Sim Lung
Grace Kong
Michael S. Hofman
Jason Callahan
Michael Michael
Rodney J. Hicks
机构：
[1] Centre for Cancer Imaging,Department of Nuclear Medicine and PET
[2] Peter MacCallum Cancer Centre,undefined
[3] Division of Cancer Medicine,undefined
[4] Neuroendocrine Tumour Unit,undefined
[5] Peter MacCallum Cancer Centre,undefined
[6] Singapore General Hospital,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
On page 4 of the original version of this article, the text “Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment” needs to be corrected.
引用
收藏
页码：323 / 323
相关论文
共 48 条
  • [31] Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study
    Okamoto, K.
    Hijioka, S.
    Goto, Y.
    Honma, Y.
    Hirano, H.
    Shoji, H.
    Sudo, K.
    Shimoi, T.
    Yonemori, K.
    Ito, K.
    Morizane, C.
    Okusaka, T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 211 - 211
  • [32] A single-center retrospective analysis of patients with advanced G3 neuroendocrine tumours
    Laffi, A.
    Spada, F.
    Bagnardi, V.
    Frassoni, S.
    Pisa, E.
    Barberis, M.
    Rubino, M.
    Fazio, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S781 - S781
  • [33] Safety and Efficacy of Peptide Receptor Radionucleotide Therapy (PRRT) in Metastatic Neuroendocrine Tumors: A US Single-Institution Experience Post-FDA Approval
    Strong, E. A.
    Gracz, M.
    Livingston, A.
    Tsai, S.
    Christians, K.
    George, B.
    Ritch, P.
    Evans, D. B.
    Wong, Y.
    Thomas, J. P.
    Clarke, C. N.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S57 - S57
  • [34] A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)
    Laffi, Alice
    Colandrea, Marzia
    Buonsanti, Giuseppe
    Frassoni, Samuele
    Bagnardi, Vincenzo
    Spada, Francesca
    Pisa, Eleonora
    Barberis, Massimo
    Rubino, Manila
    Grana, Chiara Maria
    Ceci, Francesco
    Fazio, Nicola
    DIAGNOSTICS, 2021, 11 (12)
  • [35] Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients
    Hayes, Aimee R.
    Mak, Ingrid Y. F.
    Evans, Nicholas
    Naik, Rishi
    Crawford, Alexander
    Khoo, Bernard
    Grossman, Ashley B.
    Navalkissoor, Shaunak
    Watkins, Jennifer
    Luong, Tu Vinh
    Mandair, Dalvinder
    Toumpanakis, Christos
    Thirlwell, Christina
    Caplin, Martyn E.
    Meyer, Tim
    NEUROENDOCRINOLOGY, 2021, 111 (09) : 863 - 875
  • [36] Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Baum, Richard P.
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (09) : 676 - 678
  • [37] Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)
    Apostolidis, Leonidas
    Dal Buono, Arianna
    Merola, Elettra
    Jann, Henning
    Jaeger, Dirk
    Wiedenmann, Bertram
    Winkler, Eva Caroline
    Pavel, Marianne
    CANCERS, 2021, 13 (08)
  • [38] Treatment Response and Clinical Outcomes of Poorly Differentiated (PD) Grade 3 (G3) Gallbladder Neuroendocrine Carcinomas (NEC): A Single Institution Experience
    Corbett, Virginia
    Wang, Rui
    Lowery, Maeve
    Reidy-Lagunes, Diane
    Raj, Nitya
    PANCREAS, 2018, 47 (03) : 336 - 337
  • [39] Grade 3 Pancreatic Neuroendocrine Tumor Refractory to Chemotherapy Successfully Treated with Peptide Receptor Radionuclide Therapy Leading to Conversion Surgery
    Sakaki, Kotaro
    Chiba, Mitsuru
    Iijima, Katsunori
    Goto, Takashi
    Arita, Junichi
    Tsuda, Hidehiko
    INTERNAL MEDICINE, 2025, 64 (05) : 679 - 685
  • [40] Efficacy of single- or duo-radionuclide peptide receptor radionuclide therapy (PRRT) in 1000 patients with neuroendocrine neoplasms (NENs): Analysis from a single center over more than 10 years
    Kulkarni, Harshad
    Baum, Richard
    Kaemmerer, Daniel
    Petrovitch, Alexander
    Hommann, Merten
    Hoersch, Dieter
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
12345